We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.
- Authors
Wang, Hongyue; Ma, Xinchi; Zhang, Bin; Zhang, Yaotian; Han, Ning; Wei, Linlin; Sun, Chaonan; Sun, Shichen; Zeng, Xue; Guo, Hong; Li, Yubing; Zhang, Yanyu; Zhao, Jiaming; Qin, Zilan; Liu, Zhuang; Zhang, Na
- Abstract
Purpose: To evaluate the prognosis of estrogen receptor‐positive breast cancer patients with CYP2D6*10 mutant genotypes under tamoxifen or toremifen therapy. Methods: Estrogen receptor‐positive breast cancer patients were selected and CYP2D6*10 genotypes (C/C, C/T, and T/T) were determined by Sanger sequencing. Patients were divided into tamoxifen, toremifene, or tamoxifen + toremifene groups according to prior therapy. The correlation between CYP2D6*10 genotype and disease‐free survival was analyzed. Results: In total, 293 estrogen receptor‐positive breast cancer patients treated with tamoxifen or toremifene between 2008 and 2017 were studied. Median follow‐up was 39 months (10–141). Of these, 107 (36.52%), 112 (38.23%), and 74 (25.26%) patients had C/C, C/T, and T/T genotypes, respectively. Genotype was significantly associated with disease‐free survival in tamoxifen patients. Patients with C/T and T/T genotypes showed worse disease‐free survival than patients with a C/C genotype. Genotype and disease‐free survival in toremifene and tamoxifen+toremifene patients were not correlated. Of patients with a C/T genotype, toremifene or tamoxifen+toremifene groups showed better disease‐free survival than tamoxifen patients. Although disease‐free survival of patients with a T/T genotype in the three groups was not statistically different, tamoxifen patients showed worse disease‐free survival. There was no correlation between different treatments and disease‐free survival in patients with a C/C genotype. Cox proportional hazard analysis revealed toremifene patients had a better prognosis than tamoxifen patients; toremifene was an independent protective factoremifene for disease‐free survival. Conclusions: Tamoxifen was less effective in patients with CYP2D6*10 C/T and T/T genotypes. Estrogen receptor‐positive breast cancer patients with a CYP2D6*10 mutation genotype have a better prognosis with toremifen than tamoxifen.
- Subjects
HORMONE receptor positive breast cancer; SURVIVAL analysis (Biometry); CANCER patients; TAMOXIFEN; BREAST cancer; GENOTYPES
- Publication
Asia Pacific Journal of Clinical Oncology, 2022, Vol 18, Issue 2, pe148
- ISSN
1743-7555
- Publication type
Article
- DOI
10.1111/ajco.13571